statistiche ricercatore

Continente	#
NA - Nord America	3.504
AS - Asia	304
EU - Europa	288
SA - Sud America	56
Continente sconosciuto - Info sul continente non disponibili	9
OC - Oceania	8
AF - Africa	5
Totale	4.174

Nazione	#
US - Stati Uniti d'America	3.495
SG - Singapore	117
CN - Cina	96
UA - Ucraina	55
BR - Brasile	45
RU - Federazione Russa	38
DE - Germania	34
FR - Francia	29
IE - Irlanda	28
IT - Italia	26
GB - Regno Unito	21
VN - Vietnam	21
PL - Polonia	20
FI - Finlandia	17
JP - Giappone	15
HK - Hong Kong	13
KR - Corea	11
SE - Svezia	9
AU - Australia	7
BD - Bangladesh	7
AR - Argentina	5
CA - Canada	5
AT - Austria	4
CO - Colombia	3
ID - Indonesia	3
IN - India	3
NL - Olanda	3
TW - Taiwan	3
ES - Italia	2
KZ - Kazakistan	2
MX - Messico	2
PK - Pakistan	2
TH - Thailandia	2
UZ - Uzbekistan	2
ZA - Sudafrica	2
A2 - ???statistics.table.value.countryCode.A2???	1
AE - Emirati Arabi Uniti	1
BO - Bolivia	1
BW - Botswana	1
CI - Costa d'Avorio	1
CL - Cile	1
CR - Costa Rica	1
EC - Ecuador	1
EE - Estonia	1
GT - Guatemala	1
IL - Israele	1
LT - Lituania	1
MA - Marocco	1
MY - Malesia	1
NZ - Nuova Zelanda	1
OM - Oman	1
PS - Palestinian Territory	1
SA - Arabia Saudita	1
TR - Turchia	1
Totale	4.166

Nome	#
Umeclidinium for the treatment of chronic obstructive pulmonary disease	459
Defining Phenotypes in COPD: An Aid to Personalized Healthcare	437
The effect of indacaterol during an acute exacerbation of COPD	434
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD	433
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi	430
Translational study searching for synergy between glycopyrronium and indacaterol	429
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD	428
Comorbidities of asthma	421
The clinical use of regenerative therapy in COPD	402
Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit	161
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol	140
Totale	4.174

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	77	0	0	0	5	3	9	5	7	9	8	5	26
2022/2023	189	22	23	7	18	20	36	8	27	20	0	4	4
2023/2024	38	10	3	2	0	3	16	0	1	0	0	2	1
2024/2025	177	10	44	18	10	11	10	12	5	15	21	11	10
2025/2026	424	28	22	63	64	26	16	51	43	58	18	13	22
2026/2027	111	30	13	56	12	0	0	0	0	0	0	0	0
Totale													4.174